Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Contribution

Thyrotropin-Binding Inhibitory Immunoglobulin in Patients with Graves’ Disease

Measurement and Relationship to Numeric Abnormality of T Cells

Manjula K. Gupta, Ph.D., Rafael Valenzuela, M.D., Soraya Naghshineh, Ph.D., Rebecca Turinic, B.A., I(ASCP), Ian Elliot, M.D. and O. P. Schumacher, Ph.D., M.D.
Cleveland Clinic Journal of Medicine September 1986, 53 (3) 291-297;
Manjula K. Gupta
Departments of Immunopathology and Endocrinology, The Cleveland Clinic Foundation, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Valenzuela
Departments of Immunopathology and Endocrinology, The Cleveland Clinic Foundation, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soraya Naghshineh
National Institutes of Health, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Turinic
Departments of Immunopathology and Endocrinology, The Cleveland Clinic Foundation, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Elliot
Toledo Clinic Inc., Toledo, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. P. Schumacher
Departments of Immunopathology and Endocrinology, The Cleveland Clinic Foundation, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Graves’ autoantibodies were measured by thyrotropin-binding inhibitory immunoglobulin assay (TBII) in 19 patients with Graves’ disease and in two patients with spontaneously resolving hyperthyroidism. T cell subsets in the peripheral blood were measured using monoclonal antibodies and flow cytometry (FACS II). The mean TBII index in patients with Graves’ disease was 59.7 ± 2.8 and 68% had a positive TBII index. A higher sensitivity of TBII was observed in 13 patients with exophthalmos (77% positive) than in six patients with hyperthyroidism alone (50% positive). The mean ratio of T helper inducer cells (OKT-4 positive) to T suppressor cytotoxic cells (OKT-8 positive) in Graves’ disease was 3.1 ± 2.0, which was significantly higher than controls (1.8 ± 0.4, p < 0.01). The increase in this ratio was primarily due to the decrease in the T suppressor cytotoxic cell population. Although there was a significant increase in mean ratio, eight patients had the ratio within normal range. Both patients with spontaneously resolving hyperthyroidism showed decreased T suppressor cell population but normal TBII levels. There was no significant correlation between T cell subsets and TBII in patients with Graves’ disease (r = 0.33). The results suggest that patients with Graves’ disease may have a numeric imbalance of immunoregulatory cells. However, this imbalance showed no significant relationship to the activity of the autoantibody.

Index terms
  • Goiter
  • exophthalmic
  • Immunoglobulins
  • Thyrotropin
  • Received November 1985.
  • Accepted February 1986.
  • Copyright © 1986 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 53 (3)
Cleveland Clinic Journal of Medicine
Vol. 53, Issue 3
21 Sep 1986
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Thyrotropin-Binding Inhibitory Immunoglobulin in Patients with Graves’ Disease
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Thyrotropin-Binding Inhibitory Immunoglobulin in Patients with Graves’ Disease
Manjula K. Gupta, Rafael Valenzuela, Soraya Naghshineh, Rebecca Turinic, Ian Elliot, O. P. Schumacher
Cleveland Clinic Journal of Medicine Sep 1986, 53 (3) 291-297;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Thyrotropin-Binding Inhibitory Immunoglobulin in Patients with Graves’ Disease
Manjula K. Gupta, Rafael Valenzuela, Soraya Naghshineh, Rebecca Turinic, Ian Elliot, O. P. Schumacher
Cleveland Clinic Journal of Medicine Sep 1986, 53 (3) 291-297;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A good death: is euthanasia the answer?
  • Polysomnographie, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients
  • Startle disease (hyperekplexia): a hereditary disorder with abnormal startle, falling spells, and attacks of spontaneous clonus
Show more Contribution

Similar Articles

Keywords

  • Goiter
  • Exophthalmic
  • Immunoglobulins
  • Thyrotropin

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire